A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors

NCT05668585 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

89

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors
Melanoma
NSCLC
CRC
ATC

Interventions

DRUG: CFT1946
DRUG: Trametinib
DRUG: Cetuximab

Sponsor

C4 Therapeutics, Inc.